Constellium: challenging conditions led to disappointing Q3 results and guidanceVerallia is already marketing new 2032 bonds, a precocity that raises questions.Eramet: Q3 2024 sales below expectations and acquisition of Tsingshan's lithium stake for USD 699mKering: EBIT guidance revised down again after very poor Q3Auchan to sell its Russian subsidiary (La Lettre)>...
Constellium : Challenging conditions led to disappointing Q3 results and guidanceKering : nouvelle révision en baisse de la guidance d’EBIT après un très mauvais T3Verallia commercialise déjà des nouvelles obligations 2032, une précocité qui interpelleEramet : CA T3 2024 inférieur aux attentes et acquisition de la part de Tsingshan dans le lithium pour 699 m USD Auchan s'apprêterait à vendre sa filiale en Russie (La Lettre)>...
>Q3 2024 revenue below, with organic growth disappointment - Edenred has reported total Q3 2024 revenue of € 682m, 2% below forecasts (consensus at € 695m, ODDO BHF € 688m), i.e. a reported increase of 6.1%, of which +11.5% organic, +0.9% from M&A and -6.2% from the forex effect. Organic growth in operating revenues in Q3 was +10.8% on an adjusted basis, below the consensus at 12.2% (ODDO BHF 12.6%). Among the most dynamic regions in organic terms, Latin America incre...
>Q3 2024 revenue below, with organic growth disappointment - Edenred has reported total Q3 2024 revenue of € 682m, 2% below forecasts (consensus at € 695m, ODDO BHF € 688m), i.e. a reported increase of 6.1%, of which +11.5% organic, +0.9% from M&A and -6.2% from the forex effect. Organic growth in operating revenues in Q3 was +10.8% on an adjusted basis, below the consensus at 12.2% (ODDO BHF 12.6%). Among the most dynamic regions in organic terms, Latin America incre...
>H1 results and FY 2024 positive up to EBITDA - Yesterday, before the stock market close, Edenred reported H1 2024 results above expectations (+2% on EBITDA), including a 130bp margin increase and an FY 2024 EBITDA guidance (range € 1.23bn/€ 1.30bn) in line with the consensus at € 1,264m. Nevertheless, this publication was heavily punished (share price -13% at the close), for two main reasons in our view: 1/ future adjustments to the bottom of P&L for the consensus (n...
>Résultats S1 et guidance FY24 positifs jusqu’à l’EBITDA - Edenred a publié hier avant Bourse des résultats S1 24 au-dessus des attentes (+2% sur l’EBITDA), dont une progression de la marge de 130 pb et une guidance FY 24 d’EBITDA (fourchette 1.23/1.30 Md€) en ligne avec le consensus à 1 264 M€. Néanmoins, cette publication a été lourdement sanctionnée (-13% à la clôture), pour 2 raisons principalement selon nous : 1/ les ajustements de bas de P&L à venir pour le cons...
ELO/Auchan: Towards an extremely difficult FY 2024 (La Lettre) Grünenthal acquires Valinor Pharma for USD 250mIHO: Schaeffler, Vitesco cut guidance OPmobility (formerly Plastic Omnium) continues to outperform in H1 2024 with strong sales momentumEurofins: Muddy Waters launches third report, questions the cash position again>...
ELO/Auchan : Vers un exercice 2024 très difficile (La Lettre) Grünenthal acquires Valinor Pharma for $ 250m IHO : Schaeffler, Vitesco cut guidance OPmobility (ex-Plastic Omnium) continue de surperformer au S1 2024 avec une belle dynamique commerciale Eurofins: Muddy Waters launches third report, questions the cash position again>...
>H1 2024 results beat expectations, with EBITDA 2% above estimates - Edenred’s total H1 2024 revenues came in at € 1,395m (+20% reported), 1% above the consensus at € 1,388m. In detail, operating revenues amounted to € 1,271m (consensus € 1,270m), with organic growth of 17.0% (non-adjusted basis for better comparison with consensus, +15.4% otherwise), above the consensus at 15.9%. This implies organic growth of +15.4% in Q2, slightly beating expectations at +14.9% and...
>H1 2024 results beat expectations, with EBITDA 2% above estimates - Edenred’s total H1 2024 revenues came in at € 1,395m (+20% reported), 1% above the consensus at € 1,388m. In detail, operating revenues amounted to € 1,271m (consensus € 1,270m), with organic growth of 17.0% (non-adjusted basis for better comparison with consensus, +15.4% otherwise), above the consensus at 15.9%. This implies organic growth of +15.4% in Q2, slightly beating expectations at +14.9% and...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.